recombinant ciliary neurotrophic factor

Recombinant ciliary neurotrophic factor (CNTF) is a biologic drug being developed by Staidson Biopharmaceutical for the treatment of obesity. CNTF is a neurocytokine that has shown promise in preclinical studies for its anti-obesogenic effects, acting both centrally in the hypothalamus and peripherally in tissues like skeletal muscle to modulate food intake, increase fatty acid oxidation, and improve glucose tolerance. The drug is currently in the preclinical development phase according to Staidson's pipeline. While various recombinant CNTF variants have been studied by other companies for obesity treatment in clinical trials, specific details about Staidson's formulation, brand name, and development timeline are not publicly available in the scientific literature.

Other names

CNTF recombinant protein